<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.2 20190208//EN" "JATS-archivearticle1.dtd">
<article xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" article-type="preprint">
<?all-math-mml yes?>
<?use-mml?>
<?origin ukpmcpa?>
<front>
<journal-meta>
<journal-id journal-id-type="nlm-ta">bioRxiv</journal-id>
<journal-title-group>
<journal-title>bioRxiv : the preprint server for biology</journal-title>
</journal-title-group>
<issn pub-type="ppub"/>
</journal-meta>
<article-meta>
<article-id pub-id-type="manuscript">EMS107388</article-id>
<article-id pub-id-type="doi">10.1101/2020.11.24.390039</article-id>
<article-id pub-id-type="archive">PPR243645</article-id>
<article-version article-version-type="publisher-id">2</article-version>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Article</subject>
</subj-group>
</article-categories>
<title-group>
<article-title>Ipomoeassin-F inhibits the <italic>in vitro</italic> biogenesis of the SARS-CoV-2 spike protein and its host cell membrane receptor</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>Sarah</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">4</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Roboti</surname>
<given-names>Peristera</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Duah</surname>
<given-names>Kwabena B.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zong</surname>
<given-names>Guanghui</given-names>
</name>
<xref ref-type="aff" rid="A3">3</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Schneider</surname>
<given-names>Hayden</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Shi</surname>
<given-names>Wei Q.</given-names>
</name>
<xref ref-type="aff" rid="A2">2</xref>
</contrib>
<contrib contrib-type="author">
<name>
<surname>High</surname>
<given-names>Stephen</given-names>
</name>
<xref ref-type="aff" rid="A1">1</xref>
<xref ref-type="corresp" rid="CR1">4</xref>
</contrib>
</contrib-group>
<aff id="A1">
<label>1</label>School of Biological Sciences, Faculty of Biology, Medicine and Health, University of Manchester, Manchester, M13 9PT, United Kingdom</aff>
<aff id="A2">
<label>2</label>Department of Chemistry, Ball State University, Muncie, Indiana 47306, USA</aff>
<aff id="A3">
<label>3</label>Department of Chemistry and Biochemistry, University of Maryland, College Park, Maryland 20742, USA</aff>
<author-notes>
<corresp id="CR1">
<label>4</label>Lead Contacts for correspondence: <email>sarah.okeefe@manchester.ac.uk</email>; <email>stephen.high@manchester.ac.uk</email>
</corresp>
</author-notes>
<pub-date pub-type="nihms-submitted">
<day>01</day>
<month>12</month>
<year>2020</year>
</pub-date>
<pub-date pub-type="preprint">
<day>24</day>
<month>11</month>
<year>2020</year>
</pub-date>
<permissions>
<license license-type="open-access" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">
<license-p>This work is licensed under a <ext-link ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by-nd/4.0/">CC BY-ND 4.0 International license</ext-link>.</license-p>
</license>
<license license-type="open-access" xlink:href="https://europepmc.org/downloads/openaccess">
<license-p>This preprint is made available via the <ext-link ext-link-type="uri" xlink:href="https://europepmc.org/downloads/openaccess">Europe PMC open access subset</ext-link>, for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original preprint source.</license-p>
</license>
</permissions>
<abstract>
<p id="P1">In order to produce proteins essential for their propagation, many pathogenic human viruses, including SARS-CoV-2 the causative agent of COVID-19 respiratory disease, commandeer host biosynthetic machineries and mechanisms. Three major structural proteins, the spike, envelope and membrane proteins, are amongst several SARS-CoV-2 components synthesised at the endoplasmic reticulum (ER) of infected human cells prior to the assembly of new viral particles. Hence, the inhibition of membrane protein synthesis at the ER is an attractive strategy for reducing the pathogenicity of SARS-CoV-2 and other obligate viral pathogens. Using an <italic>in vitro</italic> system, we demonstrate that the small molecule inhibitor ipomoeassin F (Ipom-F) potently blocks the Sec61-mediated ER membrane translocation/insertion of three therapeutic protein targets for SARS-CoV-2 infection; the viral spike and ORF8 proteins together with angiotensin-converting enzyme 2, the host cell plasma membrane receptor. Our findings highlight the potential for using ER protein translocation inhibitors such as Ipom-F as host-targeting, broad-spectrum, antiviral agents.</p>
</abstract>
<kwd-group>
<kwd>Cell-free translation</kwd>
<kwd>Endoplasmic reticulum (ER)</kwd>
<kwd>ER membrane complex (EMC)</kwd>
<kwd>Sec61 translocon</kwd>
<kwd>viral protein biogenesis</kwd>
</kwd-group>
</article-meta>
</front>
<body>
<sec id="S1" sec-type="intro">
<title>Introduction</title>
<p id="P2">Many viruses, including SARS-CoV-2 (<xref ref-type="bibr" rid="R31">Zhou et al., 2020</xref>; <xref ref-type="bibr" rid="R32">Zhu et al., 2020</xref>) (<xref ref-type="fig" rid="F1">Fig. 1A</xref>), hijack the host cell secretory pathway to correctly synthesise, fold and assemble important viral proteins (<xref ref-type="bibr" rid="R2">Bojkova et al., 2020</xref>; <xref ref-type="bibr" rid="R10">Gordon et al., 2020</xref>; <xref ref-type="bibr" rid="R23">Sicari et al., 2020</xref>). Hence, small molecule inhibitors of Sec61-mediated co-translational protein entry into the endoplasmic reticulum (ER) (<xref ref-type="bibr" rid="R14">Luesch and Paavilainen, 2020</xref>) have potential as broad-spectrum antivirals (<xref ref-type="bibr" rid="R12">Heaton et al., 2016</xref>; <xref ref-type="bibr" rid="R24">Shah et al., 2018</xref>). Such inhibitors offer a dual approach; first, by directly inhibiting production of key viral proteins and, second, by reducing levels of host proteins co-opted during viral infection. Hence, human angiotensin-converting enzyme 2 (ACE2) is an important host cell receptor for SARS-CoV-2 viral entry (<xref ref-type="bibr" rid="R3">Cantuti-Castelvetri et al., 2020</xref>; <xref ref-type="bibr" rid="R5">Daly et al., 2020</xref>; <xref ref-type="bibr" rid="R26">Walls et al, 2020</xref>) synthesised at the ER prior to its trafficking to the plasma membrane (<xref ref-type="bibr" rid="R27">Warner et al., 2005</xref>).</p>
<p id="P3">Our recent studies show that ipomoeassin-F (Ipom-F) (<xref ref-type="fig" rid="F1">Fig. 1B</xref>) is a potent and selective inhibitor of Sec61-mediated protein translocation at the ER membrane (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). Given that SARS-CoV-2 membrane proteins likely co-opt host mechanisms of ER entry (cf. <xref ref-type="bibr" rid="R10">Gordon et al., 2020</xref>; <xref ref-type="bibr" rid="R23">Sicari et al., 2020</xref>), we concluded that their sensitivity to Ipom-F would likely be comparable to that of endogenous Sec61 clients (<xref ref-type="fig" rid="F1">Fig. 1C</xref>; see also <xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). We, therefore, evaluated the effects of Ipom-F on SARS-CoV-2 proteins containing hydrophobic ER targeting signals (<xref ref-type="fig" rid="F1">Fig. 1D</xref>). The <italic>in vitro</italic> membrane insertion of the viral spike (S) protein and membrane translocation of the ORF8 protein are both strongly inhibited by Ipom-F, whilst several other viral membrane proteins are unaffected (<xref ref-type="fig" rid="F2">Fig. 2</xref>). Likewise, the ER integration of ACE2, an important host receptor for SARS-CoV-2 (<xref ref-type="bibr" rid="R26">Walls et al., 2020</xref>), is highly sensitive to Ipom-F (<xref ref-type="fig" rid="F2">Fig. 2</xref>).</p>
<p id="P4">We show that the principle molecular basis for the Ipom-F sensitivity of SARS-CoV-2 proteins is their dependence on Sec61, as dictated by their individual structural features and membrane topologies (<xref ref-type="fig" rid="F3">Fig. 3</xref>). Taken together, our <italic>in vitro</italic> study of SARS-CoV-2 protein synthesis at the ER highlights Ipom-F as a promising candidate for the development of a broad-spectrum, host-targeting, antiviral agent.</p>
</sec>
<sec id="S2" sec-type="results | discussion">
<title>Results and Discussion</title>
<sec id="S3">
<title>Ipom-F selectively inhibits ER translocation of the viral ORF8 and S proteins</title>
<p id="P5">To explore the ability of Ipom-F to inhibit the ER translocation of a small, yet structurally diverse, panel of SARS-CoV-2 membrane and secretory-like proteins, we first used a well-established <italic>in vitro</italic> translation system supplemented with canine pancreatic microsomes (<xref ref-type="fig" rid="F2">Fig. 2A</xref>). To facilitate the detection of ER translocation, we modified the viral ORF8, S, E, M and ORF6 proteins by adding an OPG2-tag; an epitope that supports efficient ER lumenal N-glycosylation and enables product recovery via immunoprecipitation, without affecting Ipom-F sensitivity (<xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>) (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). For viral proteins that lack endogenous sites for N-glycosylation, such as the E protein, the ER lumenal OPG2-tag acts as a reporter for ER translocation and enables their recovery of by immunoprecipitation. Where viral proteins already contain suitable sites for N-glycosylation (S and M proteins), the cytosolic OPG2-tag is used solely for immunoprecipitation. The identity of the resulting N-glycosylated species for each of these OPG2-tagged viral proteins was confirmed by endoglycosidase H (Endo H) treatment of the radiolabelled products associated with the membrane fraction prior to SDS-PAGE (<xref ref-type="fig" rid="F2">Fig. 2B, cf</xref>. lanes 1 and 2 in each panel).</p>
<p id="P6">Using ER lumenal modification of either endogenous N-glycosylation sites (viral S and M proteins) or the appended OPG2-tag (viral E and ORF8 proteins) as a reporter for ER membrane translocation, we found that 1 μM Ipom-F strongly inhibited both the translocation of the soluble, secretory-like protein ORF8-OPG2 and the integration of the type I transmembrane proteins (TMP) S-OPG2, and truncated derivatives thereof (<xref ref-type="fig" rid="F2">Fig. 2B, Fig. 2C</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S1C</xref>). Furthermore, membrane insertion of the human type I TMP, ACE2, was inhibited to a similar extent (<xref ref-type="fig" rid="F2">Fig. 2B, Fig. 2C</xref>, ~70 to ~90% inhibition for these three proteins). These results mirror previous findings showing that precursor proteins bearing N-terminal signal peptides, and which are therefore obligate clients for the Sec61-translocon, are typically very sensitive to Ipom-F-mediated inhibition (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). In the context of SARS-CoV-2 infection, wherein ACE2 acts as an important host cell receptor for the SARS-CoV-2 virus via its interaction with the viral S protein (<xref ref-type="bibr" rid="R26">Walls et al., 2020</xref>), these data suggest that an Ipom-F-induced antiviral effect might be achieved via selective reductions in the biogenesis of both host and viral proteins (cf. <xref ref-type="fig" rid="F1">Fig. 1A</xref>).</p>
<p id="P7">In contrast to the viral S and ORF8 proteins, insertion of the viral E protein was unaffected by Ipom-F (<xref ref-type="fig" rid="F2">Fig. 2B-C</xref>), consistent with its recent classification as a type III TMP (<xref ref-type="bibr" rid="R7">Duart et al., 2020</xref>). Type III TMP integration is highly resistant to Ipom-F (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>), most likely because they exploit a novel pathway for ER insertion (cf. <xref ref-type="fig" rid="F3">Fig. 3</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). We therefore conclude that the known substrate-selective inhibitory action of Ipom-F at the Sec61 translocon is directly applicable to viral membrane proteins; whereby the ER translocation of secretory proteins and type I TMPs, but not type III TMPs, is efficiently blocked by Ipom-F.</p>
<p id="P8">The viral M protein is a multi-pass TMP with its first TMD oriented so the N-terminus is exoplasmic (N<sub>exo</sub>) and hence can be considered “type III-like”. Although human multi-pass TMPs of this type typically require both the ER membrane complex (EMC) and Sec61 translocon for their authentic ER insertion (<xref ref-type="bibr" rid="R4">Chitwood et al., 2018</xref>), Ipom-F had no significant effect on the ER translocation/insertion of the M protein <italic>in vitro</italic>, as judged by the efficiency of N-glycosylation of its N-terminal domain (<xref ref-type="fig" rid="F2">Fig. 2C</xref>). We conclude that the integration of its first TMD is unaffected by Ipom-F, consistent with its use of the EMC (<xref ref-type="bibr" rid="R4">Chitwood et al., 2018</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). There is however a qualitative reduction in the intensity of both the non- and N-glycosylated forms of the M protein when compared to the control (see <xref ref-type="fig" rid="F2">Fig. 2B</xref> and <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). We speculate that this decrease may reflect an Ipom-F-induced effect on the Sec61-dependent integration of the second and/or third TM-spans of the M protein (cf. <xref ref-type="bibr" rid="R4">Chitwood et al., 2018</xref>) and our future studies will aim to resolve this question. Nevertheless, like similar host cell multi-pass TMPs that are resistant to a similar Sec61 inhibitor mycolactone (<xref ref-type="bibr" rid="R17">Morel et al., 2018</xref>), the M protein appears more resistant to Ipom-F than either the S or ORF8 proteins (<xref ref-type="fig" rid="F2">Fig 2</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S1A</xref>). In practice, the potential resistance of this highly abundant and functionally diverse class of endogenous multi-spanning membrane proteins (<xref ref-type="bibr" rid="R25">von Heijne, 2007</xref>) may limit any Ipom-F-induced cytotoxicity towards host cells.</p>
</sec>
<sec id="S4">
<title>ORF6 assumes a lumenal-facing hairpin topology in ER-derived microsomes</title>
<p id="P9">Cell-based studies of the ORF6 protein from SARS-CoV-1 suggest it has an unusual hairpin topology with both its N- and C-termini located on the exoplasmic side of the host cell membrane, to which it binds via an N-terminal amphipathic helix (<xref ref-type="bibr" rid="R19">Netland et al., 2007</xref>). To independently determine the membrane topology of SARS-CoV-2 ORF6, we prepared versions with OPG2 tags at both its N- and C-termini, or single tagged equivalents (see <xref ref-type="fig" rid="F2">Fig. 2B</xref>, schematics, OPG2-ORF6-OPG2, OPG2-ORF6 and ORF6-OPG2). Following membrane insertion, doubly tagged OPG2-ORF6-OPG2 shows significant amounts of species with 3- and 4-N-linked glycans (<xref ref-type="fig" rid="F2">Fig. 2B</xref>). This pattern confirms that the SARS-CoV-2 ORF6 protein assumes a ‘hairpin’ conformation in the ER membrane with both its N- and C-termini in the lumen (<xref ref-type="fig" rid="F2">Fig. 2B</xref>, OPG2-ORF6-OPG2). These 3- and 4-N-glycan bearing OPG2-ORF6-OPG2 species are also resistant to extraction with alkaline sodium carbonate buffer (<xref ref-type="supplementary-material" rid="SD1">Fig. S1D</xref>) and protected from added protease (<xref ref-type="supplementary-material" rid="SD1">Fig. S1E</xref>), further indicating that the majority of the ORF6 protein is stably associated with the ER membrane in a ‘hairpin’ (N<sub>exo</sub>/C<sub>exo</sub>) topology.</p>
<p id="P10">Consistent with this unusual membrane topology, we find no indication that the membrane insertion of any of our OPG2-tagged ORF6 variants is reduced by Ipom-F, strongly suggesting that its association with the inner leaflet of the ER membrane does not require protein translocation via the central channel of the Sec61 translocon (<xref ref-type="bibr" rid="R9">Gérard et al., 2020</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted). We noted a sub-set of OPG2-ORF6-OPG2 species bearing only a single N-glycan was also clearly present in the membrane-associated fraction with or without Ipom-F treatment (<xref ref-type="fig" rid="F2">Fig. 2B</xref>, OPG2-ORF6-OPG2, see 1Gly). Based on comparison to singly OPG2-tagged variants (<xref ref-type="fig" rid="F2">Fig. 2B</xref>), we conclude that OPG2-ORF6-OPG2-1Gly has its N-terminus in the ER lumen, where only one of its two consensus sites is efficiently N-glycosylated (cf. <xref ref-type="bibr" rid="R20">Nilsson and von Heijne, 1993</xref>), whilst its C-terminus is either ER luminal but non-glycosylated or remains on the cytosolic side of the membrane. In the latter case, it may be that, in addition to its hairpin topology, some fraction of ORF6 may be integrated into ER-derived microsomes as a type III TMP (cf. <xref ref-type="supplementary-material" rid="SD1">Fig. S2E</xref>; see also <xref ref-type="bibr" rid="R19">Netland et al., 2007</xref>) that is resistant to Ipom-F inhibition (this study; <xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted).</p>
</sec>
<sec id="S5">
<title>The molecular basis for SARS-CoV-2 protein sensitivity to Ipom-F</title>
<p id="P11">Having ascertained that Ipom-F inhibits the ER membrane translocation/insertion of the viral ORF8 and S proteins, but not of the ORF6, E or M proteins (<xref ref-type="fig" rid="F2">Fig. 2C</xref>), we next investigated the molecular basis for this selectivity. For these studies we employed semi-permeabilised (SP) mammalian cells, depleted of specific membrane components via siRNA-mediated knockdown, as our source of ER membrane (<xref ref-type="fig" rid="F3">Fig. 3A</xref>; <xref ref-type="bibr" rid="R28">Wilson et al., 2007</xref>). Consistent with our recent work (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted), and based on the quantitative immunoblotting of target and control gene products (<xref ref-type="supplementary-material" rid="SD1">Fig. S2A-C</xref>), we selectively depleted HeLa cells for core components of the Sec61 translocon (Sec61α-kd, ~65% reduction), the EMC (EMC5-kd, ~73% reduction) and both together (Sec61α+EMC5-kd, ~68% and ~78% reduction) prior to semi-permeabilisation with digitonin and use for <italic>in vitro</italic> ER translocation assays.</p>
<p id="P12">Following the analysis of total OPG2-tagged translation products recovered by immunoprecipitation, we found that: i) the S protein and a truncated derivative were both more strongly affected by the depletion of Sec61α than of EMC5 (<xref ref-type="fig" rid="F3">Fig. 3B</xref>, <xref ref-type="supplementary-material" rid="SD1">Fig. S2D</xref>); ii) the ORF8 protein was likewise strongly affected by Sec61α depletion but also sensitive to EMC5 depletion (<xref ref-type="fig" rid="F3">Fig. 3C</xref>); iii) the E protein showed diminished insertion efficiency after knock-down of Sec61α and EMC5, although the latter had a more pronounced effect (<xref ref-type="fig" rid="F3">Fig. 3D</xref>). In each case, the combined knockdown of Sec61α and EMC5 resulted in a reduction of membrane insertion that was either comparable to, or greater than, that achieved following the knockdown of Sec61α alone (<xref ref-type="fig" rid="F3">Figs. 3B to 3D</xref>). For the ORF6 protein, the total level of N-glycosylated OPG2-ORF6-OPG2 species was unaffected by any knockdown condition tested (<xref ref-type="fig" rid="F3">Fig. 3E</xref>). However, we note a marked increase in the proportion of potentially mis-inserted OPG2-ORF6-OPG2-1Gly species, particularly after co-depletion of EMC5 and Sec61α (see <xref ref-type="fig" rid="F3">Fig. 3E</xref>; <xref ref-type="supplementary-material" rid="SD1">Fig. S2E</xref>). We speculate that the unusual hairpin topology of the ORF6 protein may be attributed to the EMC and Sec61 complex acting in concert to provide an Ipom-F insensitive pathway for protein translocation across the ER membrane (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref>, submitted). Perturbation of this pathway seemingly increases the potential for ORF6 to mis-insert (cf. <xref ref-type="bibr" rid="R4">Chitwood et al., 2018</xref>), perhaps as a consequence of disruption to the translocation of its C-terminus (<xref ref-type="supplementary-material" rid="SD1">Fig. S2E</xref>).</p>
<p id="P13">Taken together, our data establish that, analogous to human membrane and secretory proteins, the principal molecular basis for the Ipom-F-sensitivity of the SARS-CoV-2 ORF8 and S proteins is their dependence on Sec61-mediated protein translocation into and across the ER membrane. In contrast, the E, M, and ORF6 proteins appear capable of exploiting one or more alternative membrane insertion/translocation pathways that can bypass the translocase activity of the Sec61 complex. These alternatives most likely include a recently described route for type III TMP insertion that requires the insertase function of the EMC (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted), which our data suggest is also sufficient to confer Ipom-F-resistance to the viral E protein and at least the first TM-span of the viral M protein.</p>
</sec>
</sec>
<sec id="S6" sec-type="conclusions">
<title>Concluding Remarks</title>
<p id="P14">We conclude, that Sec61-selective protein translocation inhibitors like Ipom-F hold promise as broad-spectrum antivirals that may exert a therapeutic effect by selectively inhibiting the ER translocation of viral and/or host proteins which are crucial to viral infection and propagation (<xref ref-type="bibr" rid="R15">Mast et al., 2020</xref>). In the context of SARS-CoV-2, integration of the viral S protein and its host cell receptor, ACE2, into the ER membrane is significantly reduced by Ipom-F (<xref ref-type="fig" rid="F2">Fig. 2C</xref>, <xref ref-type="fig" rid="F3">3B</xref>). Likewise, translocation of the viral ORF8 protein across the ER membrane and into its lumen is substantially diminished (<xref ref-type="fig" rid="F2">Fig. 2C</xref>, <xref ref-type="fig" rid="F3">3C</xref>). The binding of the viral S protein to cell surface ACE2 is a key step in host cell infection (<xref ref-type="bibr" rid="R6">Drew and Janes, 2020</xref>), whilst ORF8 may protect SARS-CoV-2 infected cells against host cytotoxic T lymphocytes (<xref ref-type="bibr" rid="R30">Zhang et al., 2020</xref>), making all three of these proteins viable therapeutic targets (<xref ref-type="bibr" rid="R6">Drew and Janes, 2020</xref>; <xref ref-type="bibr" rid="R13">Li et al., 2020</xref>; <xref ref-type="bibr" rid="R29">Young et al., 2020</xref>).</p>
<p id="P15">Like other small molecule inhibitors that target fundamental cellular pathways (<xref ref-type="bibr" rid="R2">Bojkova et al. 2020</xref>), the broad-ranging effects of Sec61 inhibitors on host cell membrane and secretory protein synthesis (<xref ref-type="bibr" rid="R17">Morel et al., 2018</xref>; <xref ref-type="bibr" rid="R33">Zong et al. 2019</xref>), including the strong <italic>in vitro</italic> effect of Ipom-F on ACE2 biogenesis (cf. <xref ref-type="bibr" rid="R11">Groβ et al. 2020</xref>), present an obvious hurdle to their future use. Nevertheless, given that Ipom-F is a potent inhibitor of Sec61-mediated protein translocation in cell culture models (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>), and appears well tolerated in mice (<xref ref-type="bibr" rid="R34">Zong et al., 2020</xref>), we propose that future studies investigating its effect on SARS-CoV-2 infection and propagation in cellular models are clearly warranted (cf. <xref ref-type="bibr" rid="R2">Bojkova et al. 2020</xref>).</p>
</sec>
<sec id="S7" sec-type="materials | methods">
<title>Materials and Methods</title>
<sec id="S8">
<title>Ipom-F and Antibodies</title>
<p id="P16">Ipom-F was synthesised as previously described (Zong et al., in press). Antibodies used to validate Sec61 and/or EMC subunit depletions in SP cells (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>) were purchased from Santa Cruz Biotechnology (goat polyclonal anti-LMNB1 (clone M-20, sc-6217), Bethyl Laboratories (rabbit polyclonal anti-EMC5 (A305-832-A)), Abcam (rabbit polyclonal anti-EMC6, (ab84902)), gifted by Sven Lang and Richard Zimmermann (University of Saarland, Homburg, Germany, rabbit anti-Sec61α) or as previously described (mouse monoclonal anti-OPG2 tag (<xref ref-type="bibr" rid="R16">McKenna et al., 2016</xref>) and rabbit polyclonal anti-OST48 (<xref ref-type="bibr" rid="R28">Wilson et al., 2007</xref>).</p>
</sec>
<sec id="S9">
<title>DNA constructs</title>
<p id="P17">The cDNA for human ACE2 (Uniprot: Q9BYF1) was purchased from Sino Biological (HG10108-M). cDNAs encoding the SARS-CoV-2 genes for ORF6, ORF8 and the E M and S proteins (Uniprot: P0DTC6, P0DTC8, P0DTC4, P0DTC5, P0DTC2 respectively) were kindly provided by Nevan Krogan (UCSF, US) (<xref ref-type="bibr" rid="R10">Gordon et al. 2020</xref>), amplified by PCR, subcloned into the pcDNA5 vector and constructs validated by DNA sequencing (GATC, Eurofins Genomics). ORF6-OPG2, ORF8-OPG2, M-OPG2 and S-OPG2 were generated by inserting the respective cDNAs in frame between NheI and AflII sites of a pcDNA5/FRT/V5-His vector (Invitrogen) containing a C-terminal OPG2 tag (MNGTEGPNFYVPFSNKTG). OPG2-E was generated by cloning the cDNA encoding the E-protein into the same pcDNA5-OPG2 vector using the KpnI and BamHI sites and deleting the stop codon after the OPG2 tag by site-directed mutagenesis (Stratagene QuikChange, Agilent Technologies). The N-terminal OPG2-tag of OPG2-ORF6-OPG2 was inserted by site-directed mutagenesis of ORF6-OPG2 using the relevant forward and reverse primers (Integrated DNA Technologies). Linear DNA templates were generated by PCR and mRNA transcribed using T7 polymerase.</p>
</sec>
<sec id="S10">
<title>siRNA-mediated knockdown and SP cell preparation</title>
<p id="P18">HeLa cells (human epithelial cervix carcinoma cells) were cultured in DMEM supplemented with 10% (v/v) FBS and maintained in a 5% CO<sub>2</sub> humidified incubator at 37°C. Knockdown of target genes were performed as previously described (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted) using 20 nM (final concentration) of either control siRNA (ON-TARGETplus Non-targeting control pool; Dharmacon), <italic>SEC61A1</italic> siRNA (Sec61α-kd, GE Healthcare, sequence AACACUGAAAUGUCUACGUUUUU), <italic>MMGT1</italic> siRNA (EMC5-kd, ThermoFisher Scientific, s41129) and INTERFERin (Polyplus, 409-10) as described by the manufacturer. 96 h post-initial transfection, cells were semi-permeabilsed using 80 μg/mL high purity digitonin (Calbiochem) and treated with 0.2 U Nuclease S7 Micrococcal nuclease from <italic>Staphylococcus aureus</italic> (Sigma-Aldrich, 10107921001) as previously described (<xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted; <xref ref-type="bibr" rid="R28">Wilson et al., 2007</xref>). SP cells lacking endogenous mRNA were resuspended (3×10<sup>6</sup> SP cells/mL as determined by trypan blue (Sigma-Aldrich, T8154) staining) in KHM buffer (110 mM KOAc, 2 mM Mg(OAc)<sub>2</sub>, 20 mM HEPES-KOH pH 7.2) prior to analysis by western blot, or inclusion in translation master mixes such that each translation reaction contained 2×10<sup>5</sup> cells/mL.</p>
</sec>
<sec id="S11">
<title>
<italic>In vitro</italic> ER import assays</title>
<p id="P19">Standard translation and membrane translocation/insertion assays, supplemented with nuclease-treated canine pancreatic microsomes (from stock with OD<sub>280</sub> = 44/mL) or siRNA-treated SP HeLa cells, were performed in nuclease-treated rabbit reticulocyte lysate (Promega) as previously described (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted): namely in the presence of EasyTag EXPRESS <sup>35</sup>S Protein Labelling Mix containing [<sup>35</sup>S] methionine (Perkin Elmer) (0.533 MBq; 30.15 TBq/mmol), 25 μM amino acids minus methionine (Promega), 1 μM Ipom-F, or an equivalent volume of DMSO, 6.5% (v/v) ER-derived microsomes or SP cells and ~10% (v/v) of <italic>in vitro</italic> transcribed mRNA (~500 ng/μL) encoding the relevant precursor protein. Microsomal translation reactions (20 μL) were performed for 30 min at 30°C whereas those using SP HeLa cells were performed on a 1.5× scale (30 μL translation reactions) for 1 h at 30°C. As the S protein was most efficiently synthesised using the TNT® Coupled system (<xref ref-type="supplementary-material" rid="SD1">Fig. S1B</xref>), import assays of the comparatively higher molecular weight ACE2 and S proteins (50 μL reactions) were both performed using the TNT® Coupled Transcription/ Translation system (Promega) for 90 min at 30°C as described by the manufacturer (~50 ng/μL cDNA,1 μM Ipom-F or an equivalent volume of DMSO, 12% (v/v) ER-derived microsomes or SP cells). All translation reactions were finished by incubating with 0.1 mM puromycin for 10 min at 30°C to ensure translation termination and ribosome release of newly synthesised proteins prior to analysis.</p>
</sec>
<sec id="S12">
<title>Recovery and analysis of radiolabelled products</title>
<p id="P20">Following puromycin treatment, microsomal membrane-associated fractions were recovered by centrifugation through an 80 μL high-salt cushion (0.75 M sucrose, 0.5 M KOAc, 5 mM Mg(OAc)<sub>2</sub>, 50 mM Hepes-KOH, pH 7.9) at 100,000 <italic>
<bold>g</bold>
</italic> for 10 min at 4°C and the pellet suspended directly in SDS sample buffer. To confirm the topology of ORF6 (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>), the membrane-associated fraction of the doubly-OPG2-tagged form (OPG2-ORF6-OPG2) was resuspended in KHM buffer (20 μL) and subjected to either carbonate extraction (0.1 M Na<sub>2</sub>CO<sub>3</sub>, pH 11.3) (<xref ref-type="bibr" rid="R16">McKenna et al., 2016</xref>) or a protease protection assay using trypsin (1 μg/mL) with or without 0.1% Triton X-100 (<xref ref-type="bibr" rid="R21">Ray-Sinha et al., 2009</xref>) prior to suspension in SDS sample buffer. For translation reactions using SP cells, the total reaction material was diluted with nine volumes of Triton immunoprecipitation buffer (10 mM Tris-HCl, 140 mM NaCl, 1 mM EDTA, 1% Triton X-100, 5 mM PMSF, 1 mM methionine (to prevent background from the radiolabelled methionine), pH 7.5). Samples were incubated under constant agitation with an antibody recognising the OPG2 epitope (1:200 dilution) for 16 h at 4°C to recover both the membrane-associated and non-targeted nascent chains. Samples were next incubated under constant agitation with 10% (v/v) Protein-A-Sepharose beads (Genscript) for a further 2 h at 4°C before recovery by centrifugation at 13,000 <italic>
<bold>g</bold>
</italic> for 1 min. Protein-A-Sepharose beads were washed twice with Triton immunoprecipitation buffer prior to suspension in SDS sample buffer. Where indicated, samples were treated with 1000 U of a form of Endoglycosidase H that does not co-migrate with and hence potentially distort the radiolabelled products when resolved: Endoglycosidase Hf (translation products of ~10-50 kDa; New England Biolabs, P0703S) or Endoglycosidase H (translation products of ~50-150 kDa protein substrates; New England Biolabs, P0702S). All samples were solubilised for 12 h at 37°C and then sonicated prior to resolution by SDS-PAGE (10% or 16% PAGE, 120V, 120-180 min). Gels were fixed for 5 min (20% MeOH, 10% AcOH), dried for 2 h at 65°C and radiolabelled products visualised using a Typhoon FLA-700 (GE Healthcare) following exposure to a phosphorimaging plate for 24-72 h.</p>
</sec>
<sec id="S13">
<title>Western Blotting</title>
<p id="P21">Following semi-permeabilisation, aliquots of siRNA-treated HeLa cells were suspended in SDS sample buffer, denatured for 12 h at 37°C and sonicated prior to resolution by SDS-PAGE (16% or 10% PAGE, 120V, 120-150 min). Following transfer to a PVDF membrane in transfer buffer (0.06 M Tris, 0.60 M glycine, 20% MeOH) at 300 mA for 2.5 h, PVDF membranes were incubated in 1× Casein blocking buffer (10X stock from Sigma-Aldrich, B6429) made up in TBS, incubated with appropriate primary antibodies (1:500 or 1:1000 dilution) and processed for fluorescence-based detection as described by LI-COR Biosciences using appropriate secondary antibodies (IRDye 680RD Donkey anti-Goat, IRDye 680RD Donkey anti-Rabbit, IRDye 800CW Donkey anti-Mouse) at 1:10,000 dilution. Signals were visualised using an Odyssey CLx Imaging System (LI-COR Biosciences).</p>
</sec>
<sec id="S14">
<title>Quantitation and Statistical Analysis</title>
<p id="P22">Bar graphs depict either the efficiency of membrane translocation/insertion calculated as the ratio of N-glycosylated protein relative to the amount of non-N-glycosylated protein (<xref ref-type="fig" rid="F2">Fig. 2</xref>–<xref ref-type="fig" rid="F3">3</xref>), or the efficiencies of siRNA-mediated knockdown in SP cells calculated as a proportion of the protein content when compared to the NT control (<xref ref-type="supplementary-material" rid="SD1">Fig. S2</xref>), with all control samples set to 100%. Normalised values were used for statistical comparison (one-way or two-way ANOVA; DF and F values are shown in each figure as appropriate and the multiple comparisons test used are indicated in the appropriate figure legend). Statistical significance is given as n.s., non-significant &gt;0.1; *, P &lt; 0.05; **, P &lt; 0.01; ***, P &lt; 0.001; ****, P &lt; 0.0001.</p>
</sec>
</sec>
<sec sec-type="supplementary-material" id="SM">
<title>Supplementary Material</title>
<supplementary-material content-type="local-data" id="SD1">
<label>Supplementary Information</label>
<media xlink:href="EMS107388-supplement-Supplementary_Information.pdf" mimetype="application" mime-subtype="pdf" id="N66550" position="anchor"/>
</supplementary-material>
</sec>
</body>
<back>
<ack id="S15">
<title>Acknowledgements</title>
<p>We thank Quentin Roebuck for technical assistance, Nevan Krogan (UCSF) for SARS-CoV-2 plasmids, Sven Lang (University of Saarland) for Sec61α antisera, Belinda Hall and Rachel Simmonds (University of Surrey) for useful discussions. We are indebted to Richard Zimmermann (University of Saarland) for catalyzing SARS-CoV-2 related discussions amongst the ER research community.</p>
<sec id="S16">
<title>Funding</title>
<p>This work was supported by a Wellcome Trust Investigator Award in Science 204957/Z/16/Z (S.H.), an AREA grant 2R15GM116032-02A1 from the National Institute of General Medical Sciences of the National Institutes of Health (NIH) and a Ball State University (BSU) Provost Startup Award (W.Q.S.).</p>
</sec>
</ack>
<fn-group>
<fn id="FN1" fn-type="conflict">
<p id="P23">
<bold>Competing interests</bold>
</p>
<p id="P24">The authors declare no competing interests.</p>
</fn>
<fn id="FN2" fn-type="con">
<p id="P25">
<bold>Author Contributions</bold>
</p>
<p id="P26">K.B.D., G.Z. and H.S. participated in synthesis of Ipom-F and W.Q.S supervised the synthesis; P.R. generated SARS-CoV-2 plasmids; S.O’K. performed site-directed mutagenesis and experiments; S.O’K. and S.H. designed the study, analysed the data and wrote the manuscript.</p>
</fn>
</fn-group>
<ref-list>
<ref id="R1">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Adalja</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Inglesby</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>Broad-spectrum antiviral agents: A crucial pandemic tool</article-title>
<source>Exp Rev Anti-Infect Ther</source>
<year>2019</year>
<volume>17</volume>
<fpage>467</fpage>
<lpage>470</lpage>
</element-citation>
</ref>
<ref id="R2">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Bojkova</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Klann</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Koch</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Widera</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Krause</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Ciesek</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Cinatl</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Münch</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Proteomics of SARS-CoV-2 infected host cells reveals therapy targets</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>469</fpage>
<lpage>472</lpage>
</element-citation>
</ref>
<ref id="R3">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Cantuti-Castelvetri</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Ojha</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Pedro</surname>
<given-names>LD</given-names>
</name>
<name>
<surname>Djannatian</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Franz</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Kuivanen</surname>
<given-names>S</given-names>
</name>
<name>
<surname>van der Meer</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Kallio</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Kaya</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Anastasina</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Neuropilin-1 facilitates SARS-CoV-2 cell entry and infectivity</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>856</fpage>
<lpage>860</lpage>
</element-citation>
</ref>
<ref id="R4">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Chitwood</surname>
<given-names>PJ</given-names>
</name>
<name>
<surname>Juszkiewicz</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Guna</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Shao</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Hegde</surname>
<given-names>RS</given-names>
</name>
</person-group>
<article-title>EMC is required to initiate accurate membrane protein topogenesis</article-title>
<source>Cell</source>
<year>2018</year>
<volume>175</volume>
<fpage>113</fpage>
</element-citation>
</ref>
<ref id="R5">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Daly</surname>
<given-names>JL</given-names>
</name>
<name>
<surname>Simonetti</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Klein</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>K-E</given-names>
</name>
<name>
<surname>Kavanagh Williamson</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Antón-Plágaro</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Shoemark</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Simón-Gracia</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Bauer</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Neuropilin-1 is a host factor for SARS-CoV-2 infection</article-title>
<source>Science</source>
<year>2020</year>
<volume>370</volume>
<fpage>861</fpage>
<lpage>865</lpage>
</element-citation>
</ref>
<ref id="R6">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Drew</surname>
<given-names>ED</given-names>
</name>
<name>
<surname>Janes</surname>
<given-names>RW</given-names>
</name>
</person-group>
<article-title>Identification of a druggable binding pocket in the spike protein reveals a key site for existing drugs potentially capable of combating Covid-19 infectivity</article-title>
<source>BMC Mol Cell Biol</source>
<year>2020</year>
<volume>21</volume>
<fpage>49</fpage>
</element-citation>
</ref>
<ref id="R7">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Duart</surname>
<given-names>G</given-names>
</name>
<name>
<surname>García-Murria</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Grau</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Acosta-Cáceres</surname>
<given-names>JM</given-names>
</name>
<name>
<surname>Martínez-Gil</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Mingarro</surname>
<given-names>I</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 envelope protein topology in eukaryotic membranes</article-title>
<source>Open Biol</source>
<year>2020</year>
<volume>10</volume>
<fpage>200</fpage>
<lpage>209</lpage>
</element-citation>
</ref>
<ref id="R8">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Firth</surname>
<given-names>AE</given-names>
</name>
</person-group>
<article-title>A putative new SARS-CoV protein, 3c, encoded in an ORF overlapping ORF3a</article-title>
<source>J Gen Virol</source>
<year>2020</year>
<volume>101</volume>
<fpage>1085</fpage>
<lpage>1089</lpage>
</element-citation>
</ref>
<ref id="R9">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gérard</surname>
<given-names>SF</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>BS</given-names>
</name>
<name>
<surname>Zaki</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Corfield</surname>
<given-names>KA</given-names>
</name>
<name>
<surname>Mayerhofer</surname>
<given-names>PU</given-names>
</name>
<name>
<surname>Costa</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Whelligan</surname>
<given-names>DK</given-names>
</name>
<name>
<surname>Biggin</surname>
<given-names>PC</given-names>
</name>
<name>
<surname>Simmonds</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>Higgins</surname>
<given-names>MK</given-names>
</name>
</person-group>
<article-title>Structure of the inhibited state of the Sec translocon</article-title>
<source>Mol Cell</source>
<year>2020</year>
<volume>79</volume>
<fpage>406</fpage>
<lpage>415 e7</lpage>
</element-citation>
</ref>
<ref id="R10">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Gordon</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Bouhaddou</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Xu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Obernier</surname>
<given-names>K</given-names>
</name>
<name>
<surname>White</surname>
<given-names>KM</given-names>
</name>
<name>
<surname>O’Meara</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Rezelj</surname>
<given-names>VV</given-names>
</name>
<name>
<surname>Guo</surname>
<given-names>JZ</given-names>
</name>
<name>
<surname>Swaney</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Tummino</surname>
<given-names>TA</given-names>
</name>
<etal/>
</person-group>
<article-title>A SARS-CoV-2 protein interaction map reveals targets for drug repurposing</article-title>
<source>Nature</source>
<year>2020</year>
<volume>583</volume>
<fpage>459</fpage>
<lpage>468</lpage>
</element-citation>
</ref>
<ref id="R11">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Groβ</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Jahn</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Cushman</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Bär</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Thum</surname>
<given-names>T</given-names>
</name>
</person-group>
<article-title>SARS-CoV-2 receptor ACE2-dependent implications on the cardiovascular system: from basic science to clinical implications</article-title>
<source>J Mol Cell Cardiol</source>
<year>2020</year>
<volume>144</volume>
<fpage>47</fpage>
<lpage>53</lpage>
</element-citation>
</ref>
<ref id="R12">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Heaton</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Moshkina</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Fenouil</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Gardner</surname>
<given-names>TJ</given-names>
</name>
<name>
<surname>Aguirre</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Shah</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Manganaro</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hultquist</surname>
<given-names>JF</given-names>
</name>
<name>
<surname>Noel</surname>
<given-names>J</given-names>
</name>
<etal/>
</person-group>
<article-title>Targeting viral proteostasis limits influenza virus, HIV, and Dengue virus infection</article-title>
<source>Immunity</source>
<year>2016</year>
<volume>44</volume>
<fpage>46</fpage>
<lpage>58</lpage>
</element-citation>
</ref>
<ref id="R13">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Li</surname>
<given-names>J-Y</given-names>
</name>
<name>
<surname>Liao</surname>
<given-names>C-H</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>Q</given-names>
</name>
<name>
<surname>Tan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Qiu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Ge</surname>
<given-names>X-Y</given-names>
</name>
</person-group>
<article-title>The ORF6, ORF8 and nucleocapsid proteins of SARS-CoV-2 inhibit type I interferon signalling pathway</article-title>
<source>Virus Res</source>
<year>2020</year>
<volume>286</volume>
<fpage>198074</fpage>
</element-citation>
</ref>
<ref id="R14">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Luesch</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Paavilainen</surname>
<given-names>VO</given-names>
</name>
</person-group>
<article-title>Natural products as modulators of eukaryotic protein secretion</article-title>
<source>Nat Prod Rep</source>
<year>2020</year>
<volume>37</volume>
<fpage>717</fpage>
<lpage>736</lpage>
</element-citation>
</ref>
<ref id="R15">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Mast</surname>
<given-names>FD</given-names>
</name>
<name>
<surname>Navare</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>van der Sloot</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Coulombe-Huntington</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>ut</surname>
<given-names>MP</given-names>
</name>
<name>
<surname>Baliga</surname>
<given-names>NS</given-names>
</name>
<name>
<surname>Kaushansky</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Chait</surname>
<given-names>BT</given-names>
</name>
<name>
<surname>Aderem</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Rice</surname>
<given-names>CM</given-names>
</name>
<etal/>
</person-group>
<article-title>Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality</article-title>
<source>J Cell Biol</source>
<year>2020</year>
<volume>219</volume>
<fpage>e202006159</fpage>
</element-citation>
</ref>
<ref id="R16">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>McKenna</surname>
<given-names>M</given-names>
</name>
<name>
<surname>Simmonds</surname>
<given-names>RE</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Mechanistic insights into the inhibition of Sec61-dependent co- and post-translational translocation by mycolactone</article-title>
<source>J Cell Sci</source>
<year>2016</year>
<volume>129</volume>
<fpage>1404</fpage>
<lpage>1415</lpage>
</element-citation>
</ref>
<ref id="R17">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Morel</surname>
<given-names>JD</given-names>
</name>
<name>
<surname>Paatero</surname>
<given-names>AO</given-names>
</name>
<name>
<surname>Wei</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Yewdell</surname>
<given-names>JW</given-names>
</name>
<name>
<surname>Guenin-Macé</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Van Haver</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Impens</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Pietrosemoli</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Paavilainen</surname>
<given-names>VO</given-names>
</name>
<name>
<surname>Demangel</surname>
<given-names>C</given-names>
</name>
</person-group>
<article-title>Proteomics reveals scope of mycolactone-mediated Sec61 blockade and distinctive stress signature</article-title>
<source>Mol Cell Prot</source>
<year>2018</year>
<volume>17</volume>
<fpage>1750</fpage>
<lpage>1765</lpage>
</element-citation>
</ref>
<ref id="R18">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Naqvi</surname>
<given-names>AAT</given-names>
</name>
<name>
<surname>Fatima</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Mohammad</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Fatima</surname>
<given-names>U</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>IK</given-names>
</name>
<name>
<surname>Singh</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Atif</surname>
<given-names>AM</given-names>
</name>
<name>
<surname>Hariprasad</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hasan</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Hassan</surname>
<given-names>MI</given-names>
</name>
</person-group>
<article-title>Insights into SARS-CoV-2 genome, sructure, eolution, pthogenesis and therapies: structural genomics approach</article-title>
<source>Biochim Biophys Acta Mol Basis Dis</source>
<year>2020</year>
<volume>1866</volume>
<fpage>165878</fpage>
</element-citation>
</ref>
<ref id="R19">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Netland</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ferraro</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Pewe</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Olivares</surname>
<given-names>H</given-names>
</name>
<name>
<surname>Gallagher</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Perlman</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Enhancement of murine coronavirus replication by severe acute respiratory syndrome coronavirus protein 6 requires the N-terminal hydrophobic region but not C-terminal sorting motifs</article-title>
<source>J Virol</source>
<year>2007</year>
<volume>81</volume>
<fpage>11520</fpage>
<lpage>11525</lpage>
</element-citation>
</ref>
<ref id="R20">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Nilsson</surname>
<given-names>IM</given-names>
</name>
<name>
<surname>von Heijne</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>Determination of the distance between the oligosaccharyltransferase active site and the endoplasmic reticulum membrane</article-title>
<source>J Biol Chem</source>
<year>1993</year>
<volume>268</volume>
<fpage>5798</fpage>
<lpage>5801</lpage>
</element-citation>
</ref>
<ref id="R21">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Ray-Sinha</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Cross</surname>
<given-names>BCS</given-names>
</name>
<name>
<surname>Mironov</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Wiertz</surname>
<given-names>E</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Endoplasmic reticulum-associated degradation of a degron-containing polytopic membrane protein</article-title>
<source>Mol Membr Biol</source>
<year>2009</year>
<volume>26</volume>
<fpage>448</fpage>
<lpage>464</lpage>
</element-citation>
</ref>
<ref id="R22">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>O’Keefe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Zong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Duah</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>WQ</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Type III transmembrane protein integration requires both the EMC and Sec61 complex</article-title>
<source>Submitted</source>
<year>2020</year>
</element-citation>
</ref>
<ref id="R23">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Sicari</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Chatziioannou</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Koutsandreas</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Sitia</surname>
<given-names>R</given-names>
</name>
<name>
<surname>Chevet</surname>
<given-names>E</given-names>
</name>
</person-group>
<article-title>Role of the early secretory pathway in SARS-CoV-2 infection</article-title>
<source>J Cell Biol</source>
<year>2020</year>
<volume>219</volume>
<fpage>e202006005</fpage>
</element-citation>
</ref>
<ref id="R24">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Shah</surname>
<given-names>PS</given-names>
</name>
<name>
<surname>Link</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Jang</surname>
<given-names>GM</given-names>
</name>
<name>
<surname>Sharp</surname>
<given-names>PP</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Swaney</surname>
<given-names>DL</given-names>
</name>
<name>
<surname>Johnson</surname>
<given-names>JR</given-names>
</name>
<name>
<surname>Von Dollen</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Ramage</surname>
<given-names>HR</given-names>
</name>
<name>
<surname>Satkamp</surname>
<given-names>L</given-names>
</name>
<etal/>
</person-group>
<article-title>Comparative flavivirus-host protein interaction mapping reveals mechanisms of Dengue and Zika virus pathogenesis</article-title>
<source>Cell</source>
<year>2018</year>
<volume>175</volume>
<fpage>1931</fpage>
<lpage>1945 e18</lpage>
</element-citation>
</ref>
<ref id="R25">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Von Heijne</surname>
<given-names>G</given-names>
</name>
</person-group>
<article-title>The membrane protein universe: what's out there and why bother?</article-title>
<source>J Intern Med</source>
<year>2007</year>
<volume>261</volume>
<fpage>543</fpage>
<lpage>547</lpage>
</element-citation>
</ref>
<ref id="R26">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Walls</surname>
<given-names>AC</given-names>
</name>
<name>
<surname>Park</surname>
<given-names>Y-J</given-names>
</name>
<name>
<surname>Tortorici</surname>
<given-names>MA</given-names>
</name>
<name>
<surname>Wall</surname>
<given-names>A</given-names>
</name>
<name>
<surname>McGuire</surname>
<given-names>AT</given-names>
</name>
<name>
<surname>Veesler</surname>
<given-names>D</given-names>
</name>
</person-group>
<article-title>Structure function and antigenicity of the SARS-CoV-2 spike glycoprotein</article-title>
<source>Cell</source>
<year>2020</year>
<volume>181</volume>
<fpage>P281</fpage>
<lpage>292 E6</lpage>
</element-citation>
</ref>
<ref id="R27">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Warner</surname>
<given-names>FJ</given-names>
</name>
<name>
<surname>Lew</surname>
<given-names>RA</given-names>
</name>
<name>
<surname>Smith</surname>
<given-names>AI</given-names>
</name>
<name>
<surname>Lambert</surname>
<given-names>DW</given-names>
</name>
<name>
<surname>Hooper</surname>
<given-names>NM</given-names>
</name>
<name>
<surname>Turner</surname>
<given-names>AT</given-names>
</name>
</person-group>
<article-title>Angiotensin-converting enzyme 2 (ACE2), but not ACE, is preferentially localised to the apical surface of polarised kidney cells</article-title>
<source>J Biol Chem</source>
<year>2005</year>
<volume>280</volume>
<fpage>39353</fpage>
<lpage>39362</lpage>
</element-citation>
</ref>
<ref id="R28">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Wilson</surname>
<given-names>CM</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S</given-names>
</name>
</person-group>
<article-title>Ribophorin I acts as a substrate-specific facilitator of N-glycosylation</article-title>
<source>J Cell Sci</source>
<year>2007</year>
<volume>120</volume>
<fpage>648</fpage>
<lpage>657</lpage>
</element-citation>
</ref>
<ref id="R29">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Young</surname>
<given-names>BE</given-names>
</name>
<name>
<surname>Fong</surname>
<given-names>S-W</given-names>
</name>
<name>
<surname>Chan</surname>
<given-names>YH</given-names>
</name>
<name>
<surname>Mak</surname>
<given-names>T-M</given-names>
</name>
<name>
<surname>Ang</surname>
<given-names>LW</given-names>
</name>
<name>
<surname>Anderson</surname>
<given-names>DE</given-names>
</name>
<name>
<surname>Yi-Pin Lee</surname>
<given-names>C</given-names>
</name>
<name>
<surname>Naqiah Amrun</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Lee</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shan Goh</surname>
<given-names>Y</given-names>
</name>
<etal/>
</person-group>
<article-title>Effects of a major deletion in the SARS-CoV-2 genome on the severity of infection and inflammatory response: an observational cohort study</article-title>
<source>Lancet</source>
<year>2020</year>
<volume>396</volume>
<fpage>603</fpage>
<lpage>611</lpage>
</element-citation>
</ref>
<ref id="R30">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhang</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Chen</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Luo</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Yuan</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>T</given-names>
</name>
<name>
<surname>Yu</surname>
<given-names>F</given-names>
</name>
<name>
<surname>Liu</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>Z</given-names>
</name>
<etal/>
</person-group>
<article-title>The ORF8 protein of SARS-CoV-2 mediates immune evasion through potently downregulating MHC-1</article-title>
<source>bioRxiv</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1101/2020.05.24.111823</pub-id>
</element-citation>
</ref>
<ref id="R31">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhou</surname>
<given-names>P</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>X-L</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>X-G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Si</surname>
<given-names>H-R</given-names>
</name>
<name>
<surname>Zhu</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>C-L</given-names>
</name>
<etal/>
</person-group>
<article-title>A pneumonia outbreak associated with a new coronavirus of probable bat origin</article-title>
<source>Nature</source>
<year>2020</year>
<volume>579</volume>
<fpage>270</fpage>
<lpage>273</lpage>
</element-citation>
</ref>
<ref id="R32">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zhu</surname>
<given-names>N</given-names>
</name>
<name>
<surname>Zhang</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Wang</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Li</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Yang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Song</surname>
<given-names>J</given-names>
</name>
<name>
<surname>Zhao</surname>
<given-names>X</given-names>
</name>
<name>
<surname>Huang</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Shi</surname>
<given-names>W</given-names>
</name>
<name>
<surname>Lu</surname>
<given-names>R</given-names>
</name>
<etal/>
</person-group>
<article-title>A novel coronavirus from patients with pneumonia in China, 2019</article-title>
<source>N Eng J Med</source>
<year>2020</year>
<volume>382</volume>
<fpage>727</fpage>
<lpage>733</lpage>
</element-citation>
</ref>
<ref id="R33">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Tranter</surname>
<given-names>D</given-names>
</name>
<name>
<surname>Iannotti</surname>
<given-names>MJ</given-names>
</name>
<name>
<surname>Baron</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Hall</surname>
<given-names>B</given-names>
</name>
<name>
<surname>Corfield</surname>
<given-names>K</given-names>
</name>
<name>
<surname>Paatero</surname>
<given-names>A</given-names>
</name>
<name>
<surname>Henderson</surname>
<given-names>M</given-names>
</name>
<etal/>
</person-group>
<article-title>Ipomoeassin F binds Sec61α to inhibit protein translocation</article-title>
<source>J Am Chem Soc</source>
<year>2019</year>
<volume>141</volume>
<fpage>8450</fpage>
<lpage>8461</lpage>
</element-citation>
</ref>
<ref id="R34">
<element-citation publication-type="journal">
<person-group person-group-type="author">
<name>
<surname>Zong</surname>
<given-names>G</given-names>
</name>
<name>
<surname>Hu</surname>
<given-names>Z</given-names>
</name>
<name>
<surname>Duah</surname>
<given-names>KB</given-names>
</name>
<name>
<surname>Andrews</surname>
<given-names>LE</given-names>
</name>
<name>
<surname>Zhou</surname>
<given-names>J</given-names>
</name>
<name>
<surname>O’Keefe</surname>
<given-names>S</given-names>
</name>
<name>
<surname>Whisenhunt</surname>
<given-names>L</given-names>
</name>
<name>
<surname>Shim</surname>
<given-names>JS</given-names>
</name>
<name>
<surname>Du</surname>
<given-names>Y</given-names>
</name>
<name>
<surname>High</surname>
<given-names>S</given-names>
</name>
<etal/>
</person-group>
<article-title>Ring-expansion leads to a more potent analogue of ipomoeassin F</article-title>
<source>J Org Chem</source>
<year>2020</year>
<pub-id pub-id-type="doi">10.1021/acs.joc.0c01659</pub-id>
</element-citation>
</ref>
</ref-list>
</back>
<floats-group>
<fig id="F1" position="float">
<label>Fig. 1</label>
<caption>
<title>Ipom-F as a potential inhibitor of SARS-CoV-2 viral protein synthesis.</title>
<p>
<bold>(A)</bold> Schematic of (+) ssRNA genome architecture of SARS-CoV-2 (29903 nt) containing 5’ capped mRNA with a leader sequence (LS), 3’ end poly-A tail, 5’ and 3’ UTRs and open reading frames (ORFs): ORF1a, ORF1b, spike (S), ORF3a, envelope (E), membrane (M), ORF6, ORF7, ORF8, nucleoprotein (N) and ORF10 (<xref ref-type="bibr" rid="R8">Firth, 2020</xref>; <xref ref-type="bibr" rid="R18">Naqvi et al., 2020</xref>). An important mode of SARS-CoV-2 host entry proceeds via interaction of the viral S protein with human angiotensinconverting enzyme 2 (ACE2) (<xref ref-type="bibr" rid="R26">Walls et al., 2020</xref>). (<bold>B</bold>) Structure of Ipomoeassin-F (Ipom-F), a small molecule inhibitor of Sec61-mediated protein translocation. (<bold>C</bold>) Ipom-F efficiently blocks membrane translocation of secretory proteins and insertion of single-pass type I and type II TMPs, but not insertion of type III TMPs or tail-anchored (TA) proteins. SA denotes a signal anchor. (<bold>D</bold>) Based on known/predicted membrane topology of SARS-CoV-2 proteins, and sensitivity of comparable host cell proteins (<xref ref-type="bibr" rid="R33">Zong et al., 2019</xref>; <xref ref-type="bibr" rid="R22">O’Keefe et al., 2020</xref> submitted), likely sensitivity to Ipom-F was anticipated.</p>
</caption>
<graphic xlink:href="EMS107388-f001"/>
</fig>
<fig id="F2" position="float">
<label>Fig. 2</label>
<caption>
<title>Ipom-F selectively inhibits the ER membrane translocation of SARS-CoV-2 proteins.</title>
<p>
<bold>(A)</bold> Schematic of <italic>in vitro</italic> ER import assay using pancreatic microsomes. Following translation, fully translocated/membrane inserted radiolabelled precursor proteins are recovered and analysed by SDS-PAGE and phosphorimaging. N-glycosylated species were confirmed by treatment with endoglycosidase H (Endo H). <bold>(B)</bold> Protein precursors of the human angiotensinconverting enzyme 2 (ACE2) and OPG2-tagged versions of the SARS-CoV-2 ORF8 (ORF8-OPG2), spike (S-OPG2), envelope (OPG2-E), membrane (M-OPG2) and ORF6 (a doubly-OPG2 tagged version, OPG2-ORF6-OPG2, and two singly-OPG2 tagged forms, OPG2-ORF6 and ORF6-OPG2, with predominant N-glycosylated species in bold) were synthesised in rabbit reticulocyte lysate supplemented with ER microsomes without or with Ipom-F (lanes 1 and 3). Phosphorimages of membrane-associated products resolved by SDS-PAGE with representative substrate outlines are shown. N-glycosylation was used to measure the efficiency of membrane translocation/insertion and N-glycosylated (X-Gly) versus non-N-glycosylated (0Gly) species identified using Endo H (see lane 2). <bold>(C)</bold> The relative efficiency of membrane translocation/insertion in the presence of Ipom-F was calculated using the ratio of N-glycosylated protein to non-glycosylated protein, relative to the DMSO treated control (set to 100% efficiency). Quantitations are given as mean±s.e.m for independent translation reactions performed in triplicate (<italic>n</italic>=3) and statistical significance (one-way ANOVA, DF and F values shown in the figure) was determined using Dunnett’s multiple comparisons test. Statistical significance: n.s., non-significant &gt;0.1; ****, P &lt; 0.0001.</p>
</caption>
<graphic xlink:href="EMS107388-f002"/>
</fig>
<fig id="F3" position="float">
<label>Fig. 3</label>
<caption>
<title>SARS-CoV-2 proteins are variably dependent on the Sec61 complex and/or the EMC for ER membrane translocation/insertion.</title>
<p>
<bold>(A)</bold> Schematic of <italic>in vitro</italic> ER import assay using control SP cells, or those depleted of a subunit of the Sec61 complex and/or the EMC via siRNA. Following translation, OPG2-tagged translation products (i.e. membrane-associated and non-targeted nascent chains) were immunoprecipitated, resolved by SDS-PAGE and analysed by phosphorimaging. OPG2-tagged variants of the SARS-CoV-2 <bold>(B)</bold> spike (S-OPG2), <bold>(C)</bold> ORF8 (ORF8-OPG2), <bold>(D)</bold> envelope (OPG2-E) and <bold>(E)</bold> ORF6 (OPG2-ORF6-OPG2 species (labelled as for <xref ref-type="fig" rid="F2">Fig. 2</xref>) were synthesised in rabbit reticulocyte lysate supplemented with control SP cells (lanes 1-2) or those with impaired Sec61 and/or EMC function (lanes 3-6). Radiolabelled products were recovered and analysed as in <bold>(A)</bold>. Membrane translocation/insertion efficiency was determined using the ratio of the N-glycosylation of lumenal domains, identified using Endo H (EH, lane 1), relative to the NT control (set to 100% translocation/insertion efficiency). Quantitations (<italic>n</italic>=3) and statistical significance (two-way ANOVA, DF and F values shown in the figure) determined as for <xref ref-type="fig" rid="F2">Figure 2</xref>. Statistical significance: n.s., non-significant &gt;0.1; *, P &lt; 0.05; **, P &lt; 0.01; ***, P &lt; 0.001; ****, P &lt; 0.0001.</p>
</caption>
<graphic xlink:href="EMS107388-f003"/>
</fig>
</floats-group>
</article>
